Cantor Fitzgerald Issues Positive Forecast for KALV Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Investment analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Monday, July 14th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the specialty pharmaceutical company will earn ($2.83) per share for the year, up from their prior forecast of ($2.90). The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

Several other equities research analysts also recently issued reports on KALV. HC Wainwright raised their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Leerink Partners raised their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, July 7th. JMP Securities raised their target price on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a “market outperform” rating in a research note on Tuesday, July 8th. Finally, Jones Trading reiterated a “buy” rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $26.29.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $15.79 on Wednesday. The firm has a 50-day moving average of $12.74 and a 200-day moving average of $11.37. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $16.32. The company has a market cap of $788.71 million, a price-to-earnings ratio of -4.28 and a beta of -0.04.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($2.86). During the same period in the previous year, the company posted ($1.07) earnings per share.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in KALV. Aquatic Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals during the 4th quarter worth about $44,000. Earned Wealth Advisors LLC bought a new position in shares of KalVista Pharmaceuticals during the 1st quarter worth about $44,000. GAMMA Investing LLC boosted its position in shares of KalVista Pharmaceuticals by 567.3% during the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock worth $51,000 after purchasing an additional 3,767 shares in the last quarter. CWM LLC boosted its position in shares of KalVista Pharmaceuticals by 12,636.1% during the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 4,549 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 5,502 shares during the last quarter.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of the company’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the sale, the chief executive officer owned 369,595 shares of the company’s stock, valued at approximately $5,798,945.55. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 2,776 shares of the company’s stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider directly owned 106,611 shares in the company, valued at $1,262,274.24. This trade represents a 2.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,878 shares of company stock worth $723,617 in the last ninety days. Insiders own 10.50% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).